Significance of Oligomeric and Fibrillar Species in Amyloidosis: Insights into Pathophysiology and Treatment

Amyloidosis is a term referring to a group of various protein-misfolding diseases wherein normally soluble proteins form aggregates as insoluble amyloid fibrils. How, or whether, amyloid fibrils contribute to tissue damage in amyloidosis has been the topic of debate. In vitro studies have demonstrat...

Full description

Bibliographic Details
Main Authors: Haruki Koike, Yohei Iguchi, Kentaro Sahashi, Masahisa Katsuno
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Molecules
Subjects:
Online Access:https://www.mdpi.com/1420-3049/26/16/5091
_version_ 1827684490548346880
author Haruki Koike
Yohei Iguchi
Kentaro Sahashi
Masahisa Katsuno
author_facet Haruki Koike
Yohei Iguchi
Kentaro Sahashi
Masahisa Katsuno
author_sort Haruki Koike
collection DOAJ
description Amyloidosis is a term referring to a group of various protein-misfolding diseases wherein normally soluble proteins form aggregates as insoluble amyloid fibrils. How, or whether, amyloid fibrils contribute to tissue damage in amyloidosis has been the topic of debate. In vitro studies have demonstrated the appearance of small globular oligomeric species during the incubation of amyloid beta peptide (Aβ). Nerve biopsy specimens from patients with systemic amyloidosis have suggested that globular structures similar to Aβ oligomers were generated from amorphous electron-dense materials and later developed into mature amyloid fibrils. Schwann cells adjacent to amyloid fibrils become atrophic and degenerative, suggesting that the direct tissue damage induced by amyloid fibrils plays an important role in systemic amyloidosis. In contrast, there is increasing evidence that oligomers, rather than amyloid fibrils, are responsible for cell death in neurodegenerative diseases, particularly Alzheimer’s disease. Disease-modifying therapies based on the pathophysiology of amyloidosis have now become available. Aducanumab, a human monoclonal antibody against the aggregated form of Aβ, was recently approved for Alzheimer’s disease, and other monoclonal antibodies, including gantenerumab, solanezumab, and lecanemab, could also be up for approval. As many other agents for amyloidosis will be developed in the future, studies to develop sensitive clinical scales for identifying improvement and markers that can act as surrogates for clinical scales should be conducted.
first_indexed 2024-03-10T08:31:57Z
format Article
id doaj.art-2aa82b95237c4529a1a22217e8ba41a9
institution Directory Open Access Journal
issn 1420-3049
language English
last_indexed 2024-03-10T08:31:57Z
publishDate 2021-08-01
publisher MDPI AG
record_format Article
series Molecules
spelling doaj.art-2aa82b95237c4529a1a22217e8ba41a92023-11-22T08:56:31ZengMDPI AGMolecules1420-30492021-08-012616509110.3390/molecules26165091Significance of Oligomeric and Fibrillar Species in Amyloidosis: Insights into Pathophysiology and TreatmentHaruki Koike0Yohei Iguchi1Kentaro Sahashi2Masahisa Katsuno3Department of Neurology, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, JapanDepartment of Neurology, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, JapanDepartment of Neurology, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, JapanDepartment of Neurology, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, JapanAmyloidosis is a term referring to a group of various protein-misfolding diseases wherein normally soluble proteins form aggregates as insoluble amyloid fibrils. How, or whether, amyloid fibrils contribute to tissue damage in amyloidosis has been the topic of debate. In vitro studies have demonstrated the appearance of small globular oligomeric species during the incubation of amyloid beta peptide (Aβ). Nerve biopsy specimens from patients with systemic amyloidosis have suggested that globular structures similar to Aβ oligomers were generated from amorphous electron-dense materials and later developed into mature amyloid fibrils. Schwann cells adjacent to amyloid fibrils become atrophic and degenerative, suggesting that the direct tissue damage induced by amyloid fibrils plays an important role in systemic amyloidosis. In contrast, there is increasing evidence that oligomers, rather than amyloid fibrils, are responsible for cell death in neurodegenerative diseases, particularly Alzheimer’s disease. Disease-modifying therapies based on the pathophysiology of amyloidosis have now become available. Aducanumab, a human monoclonal antibody against the aggregated form of Aβ, was recently approved for Alzheimer’s disease, and other monoclonal antibodies, including gantenerumab, solanezumab, and lecanemab, could also be up for approval. As many other agents for amyloidosis will be developed in the future, studies to develop sensitive clinical scales for identifying improvement and markers that can act as surrogates for clinical scales should be conducted.https://www.mdpi.com/1420-3049/26/16/5091AA amyloidosisAL amyloidosisAlzheimer’s diseaseamyotrophic lateral sclerosisATTR amyloidosisdementia
spellingShingle Haruki Koike
Yohei Iguchi
Kentaro Sahashi
Masahisa Katsuno
Significance of Oligomeric and Fibrillar Species in Amyloidosis: Insights into Pathophysiology and Treatment
Molecules
AA amyloidosis
AL amyloidosis
Alzheimer’s disease
amyotrophic lateral sclerosis
ATTR amyloidosis
dementia
title Significance of Oligomeric and Fibrillar Species in Amyloidosis: Insights into Pathophysiology and Treatment
title_full Significance of Oligomeric and Fibrillar Species in Amyloidosis: Insights into Pathophysiology and Treatment
title_fullStr Significance of Oligomeric and Fibrillar Species in Amyloidosis: Insights into Pathophysiology and Treatment
title_full_unstemmed Significance of Oligomeric and Fibrillar Species in Amyloidosis: Insights into Pathophysiology and Treatment
title_short Significance of Oligomeric and Fibrillar Species in Amyloidosis: Insights into Pathophysiology and Treatment
title_sort significance of oligomeric and fibrillar species in amyloidosis insights into pathophysiology and treatment
topic AA amyloidosis
AL amyloidosis
Alzheimer’s disease
amyotrophic lateral sclerosis
ATTR amyloidosis
dementia
url https://www.mdpi.com/1420-3049/26/16/5091
work_keys_str_mv AT harukikoike significanceofoligomericandfibrillarspeciesinamyloidosisinsightsintopathophysiologyandtreatment
AT yoheiiguchi significanceofoligomericandfibrillarspeciesinamyloidosisinsightsintopathophysiologyandtreatment
AT kentarosahashi significanceofoligomericandfibrillarspeciesinamyloidosisinsightsintopathophysiologyandtreatment
AT masahisakatsuno significanceofoligomericandfibrillarspeciesinamyloidosisinsightsintopathophysiologyandtreatment